Sign In
Buy CATX
$3.56
-0.0400 (-1.11%)
At Close: Jun 03, 2026
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results
07:00am, Friday, 24'th Oct 2025
SEATTLE, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatme
Perspective Therapeutics, Inc. (CATX) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO Transcript
05:05pm, Monday, 20'th Oct 2025
Perspective Therapeutics, Inc. (NYSE:CATX ) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO October 20, 2025 8:30 AM EDT Company Participants Annie Cheng - Vice President of Invest
SEATTLE, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for canc
Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors
07:00am, Wednesday, 03'rd Sep 2025
SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for canc
Perspective Therapeutics to Participate in Upcoming September Conferences
07:00am, Tuesday, 26'th Aug 2025
SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cance
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results
06:45am, Wednesday, 13'th Aug 2025
SEATTLE, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company
Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy
08:53am, Saturday, 02'nd Aug 2025
Perspective Therapeutics' pipeline, led by VMT-a-NET, shows promising safety and early efficacy, but lacks clear superiority over existing therapies like Lutathera so far. The company maintains a stro
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025
12:45pm, Thursday, 24'th Jul 2025
SEATTLE, July 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
07:00am, Tuesday, 15'th Jul 2025
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting
08:00am, Saturday, 21'st Jun 2025
SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments
SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cance
SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments f
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results
04:36pm, Monday, 12'th May 2025
SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company
Perspective Therapeutics to Participate in Upcoming May Investor Conferences
07:00am, Thursday, 01'st May 2025
SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancer
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting
12:25pm, Wednesday, 23'rd Apr 2025
SEATTLE, April 23, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments
